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Purpose: This study was conducted to investigate the mutation spectrum of the cytochrome P450 gene (CYP1B1) in
Chinese patients with primary congenital glaucoma (PCG).
Methods: The coding regions of CYP1B1 from 41 Chinese PCG patients were analyzed using polymerase chain reaction
(PCR) and heteroduplex analysis-single strand conformation polymorphism (HA-SSCP) followed by subsequent cloning
and bidirectional sequencing. New variants were confirmed by restriction fragment length polymorphism (RFLP) analysis
in 80 normal Chinese controls.
Results: Six distinct mutations, four of which are novel, were identified in 14.6% (6/41) of all patients. The CYP1B1
mutations in two patients were homozygous, and the other four patients were compound heterozygous. Beyond the four
novel mutations (g.4531_4552del22bp, g.4633delC, p.S336Y, and p.I471S), two reported missense mutations (R469W
and R390H) were also identified. The missense mutation, R390H, was involved in 9.8% (4/41) of patients in our study.
None of the novel mutations was observed in any of the 80 controls.
Conclusions: Our results support the premise that CYP1B1 is a major gene for PCG, appearing to be responsible for the
disease in roughly one in six Chinese PCG patients. The R390H mutation was identified as a predominant CYP1B1 allele
among the Chinese PCG patients in our study. This observation emphasizes the importance of mutational screening of
CYP1B1, especially for the R390H mutation in Chinese patients.
A rare but severe primary congenital form of glaucoma
(PCG; OMIM 231300), which usually manifests itself from
birth to three years of age, is a significant cause of blindness
in children [1,2]. In primary congenital glaucoma (PCG), the
ocular developmental defects of the trabecular meshwork and
anterior chamber angle lead to the obstruction of aqueous
outflow and subsequent increased intraocular pressure (IOP).
PCG is detected clinically in neonates and infants by noting
the typical symptoms of photophobia and epiphora as well as
signs of globe enlargement, edema and opacification of the
cornea, and ruptures involving Descemet’s membrane, all of
which result from the elevated IOP [3].
Even though three different chromosomal loci for PCG
on 2p21 (glaucoma 3, primary congenital, A [GLC3A, OMIM
231300]) [4], 1p36 (GLC3B) [5], and 14q24.3 (GLC3C) [6]
have  been  mapped,  the  cytochrome  P450  gene,  CYP1B1
(OMIM  601771),  located  in  the  GLC3A  locus,  has  been
characterized. The human CYP1B1 consists of three exons
with the translated region beginning at the 5′ end of the second
exon.  It  encodes  a  member  of  the  cytochrome  P450
superfamily, subfamily I. The CYP1B1 product is a 543 amino
acid  long  protein  that  contains  conserved  core  structures
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(CCS), which includes four helix bundles (helices D, I, and L
and the antiparallel helix E), helices J and K, β-sheets 1 and
2, a heme-binding region, and a “meander” region. Most of
these regions are located within the COOH-terminal half of
the CYP1B1 protein and are expected to be involved in heme-
binding and proper folding of the molecule [7]. CYP1B1 is a
membrane-bound  monomeric  mixed  function  mono-
oxygenase  that  is  expressed  primarily  in  the  trabecular
meshwork but also in the posterior segment of the eye, notably
in the neuroretina, and other tissues such as the adrenal gland,
the ovary, the testis, the lung, the uterus and the kidney [8].
The protein is probably associated with the metabolism of
compounds that are critical to the developing eye [9].
Mutations  in  CYP1B1  is  the  predominant  cause  of
autosomal recessive inherited PCG that has been reported in
various ethnic backgrounds [6,10-13]. So far, the spectrum of
CYP1B1 mutations causing PCG in the Chinese population is
not yet well understood. Herein, we investigated CYP1B1
mutations in 41 unrelated Chinese patients with PCG.
METHODS
Patient recruitment: The study followed the tenets of the
Declaration  of  Helsinki  with  written  informed  consent
obtained from all patients or from their parents if their age was
less than 18. Forty-one patients with PCG were recruited from
the glaucoma clinics at Zhongshan Ophthalmic Center at Sun
Yat-sen University (Guangzhou, China). After undergoing a
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432complete eye examination including slit-lamp biomicroscopy,
optic nerve examination, and measurement of IOP by Perkins
or Goldmann tonometry, all enrolled patients were diagnosed
with PCG. Subjects with secondary causes of glaucoma (e.g.,
trauma, uveitis, steroid-induced- or neovascular glaucoma,
and  other  associated  ocular  or  systemic  anomalies)  were
excluded.  PCG  was  defined  according  to  the  following
criteria: age of onset less than three years; IOP greater than 21
mmHg  without  any  treatment;  optic  nerve  cupping,  and
moreover, rupture of Descemet’s membrane, or horizontal
corneal diameter greater than 12 mm with or without corneal
edema.  Patients  older  than  three  years  without  secondary
causes but with buphthalmos were considered to have PCG.
In our study, six (14.6%) patients had unilateral PCG, and
neither a family history of PCG nor parental consanguinity
was established in any of the 41 unrelated Chinese patients.
Eighty ethnically matched normal individuals without any
ocular disorders served as controls.
Mutation screening: Blood samples were collected from 41
patients and 80 controls after informed consent was received.
Genomic DNA was extracted from leucocytes by proteinase
K-phenol-chloroform extraction. Ten sets of primers (Table
1)  were  used  to  amplify  the  coding  regions  of  CYP1B1
(U56438). Polymerase chain reaction (PCR) amplification
was performed in a 25 l volume by means of a touchdown
PCR program with an annealing temperature decreasing from
64 °C to 58 °C or 56 °C over 10 cycles followed by 30 cycles
with  an  annealing  temperature  of  58  °C  or  56  °C.
Subsequently,  the  PCR  products  were  analyzed  by
heteroduplex  analysis-single  strand  conformation
polymorphism (HA-SSCP) as described previously [14]. PCR
products showing aberrant banding patterns on SSCP were
sequenced  using  the  ABI  BigDye  Terminator  Cycle
Sequencing Kit v3.1 (Applied Biosystems, Foster City, CA)
in  accordance  with  the  manufacturer’s  recommendations,
using an ABI 377 or 3100 sequencer (Applied Biosystems).
The fragment containing the entire second exon was amplified
for sequencing by the first set of forward primers and the sixth
set of reverse primers (Table 1), the third exon amplified by
the seventh set of forward primers and the tenth set of reverse
primers  (Table  1).  Each  variant  was  confirmed  by
bidirectional sequencing. Comparative sequencing analysis
between  different  samples  and  the  standard  sequence
(U56438) was performed using the SeqManII program of the
Lasergene  package  (DNAStar  Inc.,  Madison,  WI).
Heterozygous  deletions  (g.4531_4552del22bp  and  g.
4633delC) were identified using a monoclone followed by
direct sequencing.
Four mutations were confirmed by restriction fragment
length polymorphism (RFLP), I471S by BtsI, S336Y by AhdI,
g.4531_4552del22bp  by  TfiI,  and  g.4633delC  by  SmlI.
Digestion  products  were  loaded  onto  an  8%  (49:1)
polyacrylamide/0.5X TBE gel and resolved at 18 W for about
2 h. Subsequently, the gel was silver stained as previously
described, similar to how it was used in SSCP analysis [15].
The two missense mutations were analyzed by multiple amino
acid  sequence  alignment  of  CYP1B1  and  CYP1B2  from
different  species  using  the  MegAlign  program  of  the
Lasergene package (DNAStar Inc.).
RESULTS
The complete coding region of CYP1B1 from all 41 PCG
patients was screened using HA-SSCP followed by direct
TABLE 1. PRIMER PAIRS FOR CYP1B1 MUTATION ANALYSIS.
ID Primer sequences (5′→3′)   Product
length (bp)
     Annealing
temperature (°C)
CYP1F CTGAGTGTCACGCCTTCT 261 56
CYP1R CGAGCGAACGAGAGGTGA
CYP2F CGTTTGCGTGGCCACTGAT 256 56
CYP2R TCCGAGTAGTGGCCGAAAG
CYP3F CACGGCGCAGCGCAGATGC 242 56
CYP3R GCCGAAACACACGGCACTCAT
CYP4F CCGTGGCCAACGTCATGAGT 256 56
CYP4R GGCCGAAGGCTTTCGCAGT
CYP5F CGAGCAGCTCAACCGCAACT 183 56
CYP5R GCCGGTACGTTCTCCAAATC
CYP6F AACGTACCGGCCACTATCAC 231 56
CYP6R GACGCGATCTTGGTTTTGAG
CYP7F CACTGAGCTAGATAGCCTAT 253 58
CYP7R GGAGAAGCGCATGGCTTCAT
CYP8F ATGGGTGACCAGCCCAACCT 238 58
CYP8R GGCCGTCCTTGTCCAAGAAT
CYP9F TGGCCTAACCCGGAGAACTT 210 58
CYP9R CATTTTCGCAGGCTCATTTGG
CYP10F GGCTCACCAGTGCGATTTCAG 228 58
CYP10R ACTCCTCATCTCCGAAGATG
Listed are primer sequences, sizes of PCR products, and the annealing temperature used for the amplification. Ten pairs of
primers were used to amplify and sequence the CYP1B1 genomic segments.
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433sequencing. We identified six different mutations, four of
which are novel, in six patients with bilateral PCG. We also
identified five reported polymorphisms, g.3793 T>C, g.3947
C>G (R48G), g.4160 G>T (A119S), g.8131 C>G (L432V),
and g.8184 C>T (D449D) [6]. Details of the six patients and
mutations are summarized in Table 2.
Analysis of the four novel mutations: The four novel
mutations (Figure 1B) included two frame-shift mutations,
both of them in the second exon, leading to deletions of 22 bp
(g.4531_4552del22bp, reference sequence U56438) and 1 bp
(g.4633del  C),  and  two  missense  mutations  (S336Y  and
I471S). Except for the homozygous I471S, each of the other
three  new  mutations  was  in  the  compound  heterozygous
condition with another mutation. All four mutations changed
one restriction site, g.4531_4552del22bp (TfiI) and I471S
(BtsI) created new restriction sites, and g.4633delC (SmlI)
and S336Y (AhdI) resulted in the loss of restriction sites.
Using special restriction endonuclease digestion (Figure 1A),
we failed to identify these four novel mutations in any of the
80 controls.
Because of the creation of premature stop codons, both
deletions were predicted to truncate the CYP1B1 open reading
frame.  The  frameshift  mutation,  g.4531_4552del22bp
(p.D242DfsX28), which affects the third nucleotide of codon
242, introduces a premature stop codon at codon 270, and g.
4633delC (p.F276FfsX1) creates a premature stop codon at
codon 277. Because the COOH-terminal half of the CYP1B1
protein is expected to be involved in heme-binding and proper
folding of the molecule [7], the two deletions eliminating the
essential COOH-terminal part of the P450 protein obviously
affected the structure and damaged the function of CYP1B1.
Because  the  novel  missense  mutations  altered
hydrophobic properties at their sites (I471S) or consisted of
replacement of the micromolecular Ser side chain of by the
large hydrophilic Tyr (S336Y), the I471S and the S336Y
could directly affect the helix L and the helix I of the conserved
core structures (CCS) of CYP1B1 protein, respectively. These
mutations  could  interfere  with  heme  incorporation,  by
affecting the CCS that controls the proper folding and heme-
binding ability of P450 molecules [7,16,17]. Comparative
amino acid sequence alignment of seven different cytochrome
P450 proteins revealed that the two novel missense mutations
(S336Y and I471S) occurred at highly conserved positions
(Figure 1D).
Other mutations: Apart from these four novel mutations,
two reported missense mutations were also found in our study.
The R390H mutation previously reported in Pakistani and
Indian patients [7,18] was the most frequent mutant allele
identified in our study population. It exhibited heterozygosity
or homozygosity in 9.8% (4/41) of the patients recruited.
Another missense mutation, R469W, which has been reported
in British and Turkish patients [7], was associated with the
frameshift mutation (g.4633del C) in one patient in our study.
DISCUSSION
Because of ethnic differences and geographical variations, the
prevalence of CYP1B1 mutations varies in different patient
populations from 100% in Saudi Arabians with PCG to 20%
among  the  Japanese  with  PCG  [6,10-13].  In  our  study,
CYP1B1 mutations were found in 6 out of our 41 Chinese PCG
patients (14.6%).
Our study supports the contention that CYP1B1 is a major
gene involved in PCG, though the mutation rate in our study
TABLE 2. SUMMARY OF CLINICAL FINDINGS AND CYP1B1 MUTATIONS IN SIX PCG PATIENTS.
Age at
diagnosis Mutation 1 Mutation 2 SNP VA OD VA OS






























Clinical data, CYP1B1   mutations, and single nucleotide polymorphisms (SNP, g.8131C>G) of the six PCG patients are
summarized. GenBank U56438 ; “F”: female; “M”: male; “Y”: years; “Mo”: months; “SNP”: g.8183C>G(L432V); “LP”: light
perception; “CF”: count fingers; “VA”: visual acuity.
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Patient Genderwas less than the 20% level reported in sporadic Japanese PCG
patients  [6,10-13].  As  for  mutation  screenings  among
different populations, the potential for bias (differences in the
criterion for patient recruitment and the proportion of parental
consanguinity  among  patients,  etc.)  must  be  considered.
Populations who have a higher rate of consanguinity exhibit
a higher frequency of CYP1B1 mutations among PCG patients
than ethnically diverse populations (like the Japanese and
Chinese)  [11,12].  The  unevenness  in  the  distribution  of
CYP1B1 mutations among different populations may be due
to  founder  effects  [19].  Because  CYP1B1  mutations  are
responsible for only about 14.6% of Chinese PCG patients, it
is imperative that other causes of PCG be investigated in
future studies.
Although  different  CYP1B1  mutation  spectrums  have
been discovered in different populations with PCG, certain
mutations occur repeatedly in ethnically distinct populations.
Analysis of the constructed haplotype for CYP1B1 was used
to study these mutations [20-22]. If genetic markers on the
mutant chromosomes are identical, the mutation is a founder
mutation. However, if different genetic markers are observed,
the  recurrence  of  the  mutations  would  be  explained  by  a
mutation  ‘hot  spot’.  R368H,  which  is  reported  as  a
predominant CYP1B1 allele in Indian PCG patients (17.8%)
[20], and G61E, which is found in 72% of the Saudi-Arabians
Figure 1. Four novel CYP1B1 mutations observed in Chinese patients with PCG. A: Result of the restriction fragment length polymorphism
(RFLP) analysis of the four mutations. “M”: marker; “P”: PCR patient products; “+”: restriction fragments from patients; “−”: restriction
fragments from controls. The size of the fragments is indicated by an arrowhead. B: Sequencing of the four novel mutations and normal
controls are shown. As for the deletions, sequencing of the cloning was shown. The exact mutation was labeled under each sequence according
to the nomenclature recommended by HGVS. C: Pictures of the patient with I471S show the larger cornea and bigger eyeball. Photos of the
anterior segment and B-mode ultrasonography of both eyes are also shown. D: Sequence alignment of seven different cytochrome P450
proteins revealed that the two novel missense mutations (S336Y, I471S) occurred at highly conserved positions.
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435[8] and 47% of the Kuwaiti PCG patients [23], were identified
as founder mutations in the Western world [22]. Because
founder mutations are also the oldest mutations, they may be
the most frequent mutations in PCG patients in ethnically
heterogeneous populations.
The R390H mutation, which has been reported in 4.7%
of Indian [19] and 3.6% of Pakistani [12] PCG patients, was
the most frequent mutation observed in our study samples
where 9.8% (4/41) of PCG patients were found to have this
mutation.  This  is  the  highest  reported  frequency  of  this
mutation of all ethnic backgrounds studied so far. As for the
predominant mutation, R390H, found in our study, further
studies will be needed to clarify whether this is the founder
mutation in Chinese patients or just a mutation ‘hot spot’.
Either way, screening for R390H may be a method for rapid
detection of potential carriers and affected individuals.
The  five  reported  polymorphisms,  g.3793T>C,  g.
3947C>G  (R48G),  g.4160  G>T(A119S),  g.8131C>G
(L432V),  and  g.8184C>T  (D449D),  construct  the  5′-
CCGGTA-3′  haplotype  associated  with  most  CYP1B1
mutations in the Western world [22]. The g.8131G (V432)
polymorphism has the highest frequency in Brazilian PCG
patients compared to normal controls [6]. Our results failed to
show the association of the 5′-CCGGTA-3′ haplotype with
CYP1B1 mutations in Chinese patients, and g.8131G not g.
8131C was found to be associated with all the patients with
CYP1B1 mutations (Table 2). The mutations identified in
Chinese patients tend to be present on other haplotypes.
In summary, this study shows that 14.6% of Chinese
patients studied carried CYP1B1 mutations and that R390H
appears to be the predominant mutant allele causing PCG in
Chinese patients. In light of these findings, we suggest that
screening  for  this  mutation  should  be  a  priority  for  the
scientific community.
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